We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
- Authors
Blonde, L; Klein, E J; Han, J; Zhang, B; Mac, S M; Poon, T H; Taylor, K L; Trautmann, M E; Kim, D D; Kendall, D M
- Abstract
Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30-week placebo-controlled trials. This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET).
- Publication
Diabetes, obesity & metabolism, 2006, Vol 8, Issue 4, p436
- ISSN
1462-8902
- Publication type
Journal Article
- DOI
10.1111/j.1463-1326.2006.00602.x